

TAKAFULINK DANA EKUITI GLOBAL

All information as at 31 May 2020 unless otherwise stated


Semua maklumat adalah seperti pada 31 Mei 2020 melainkan jika dinyatakan

Objective / Objektif Dana

Takafulink Dana Ekuiti Global (The Fund) aims to provide capital appreciation by investing in Shariah-compliant investments with exposure to the global equity markets.

Takafulink Dana Ekuiti Global (Dana) bertujuan untuk menyediakan peningkatan nilai modal dengan melabur dalam sekuriti patuh Syariah melalui pendedahan terhadap pasaran ekuiti global.

Where the Fund invests Komposisi Pelaburan Dana



Asset Allocation Peruntukan Aset


	% NAV
1	Aberdeen Standard Islamic World 100.16 Equity Fund
2	Cash, Deposits & Others -0.16

Fund Details / Maklumat Terperinci Dana

Investment Manager / Pengurus Pelaburan	Prudential BSN Takaful Berhad (200601020898)
Inception Date / Tarikh Diterbitkan	08/07/2019
Current Fund Size / Saiz Dana Terkini	RM1,104,510.39
Annual Fund Management Charge / Caj Pengurusan Dana Tahunan	1.5% p.a.
Current NAV / NAB Terkini	RM1.05053

How the Fund has performed / Prestasi Dana

Performance Graph / Jaduan Prestasi Dana
Takafulink Dana Ekuiti Global Vs. MSCI ACWI Islamic (Shariah) Index



Total Price Movement Over the Following Periods / Jumlah Pergerakan Harga Dalam Tempoh Tersebut

	1 month	3 months	6 months	1 year	3 years	5 years	Since Inception
Price Movement / Pergerakan Harga	5.61%	4.57%	0.72%	NA	NA	NA	5.05%
Benchmark / Penanda Aras	5.34%	10.50%	-2.62%	NA	NA	NA	1.46%
Outperformance / Perbezaan Prestasi	0.27%	-5.93%	3.34%	NA	NA	NA	3.59%

TAKAFULINK DANA EKUITI GLOBAL

All information as at 31 May 2020 unless otherwise stated

Semua maklumat adalah seperti pada 31 Mei 2020 melainkan jika dinyatakan

Monthly Update / Laporan Bulanan Terkini

Global equities rose steadily through May in most major currencies. Investors were optimistic that the peak of the covid-19 outbreak has now passed in many countries, and most major economies were on the path of recovery. Continued fiscal support further underpinned stocks. Japan rolled out a larger-than-expected 117 trillion yen supplementary budget, while the European Commission proposed a €750 billion recovery fund. China's policymakers expanded an already-augmented fiscal deficit, to a record 15.2% of GDP. However, renewed US-China tensions cast a shadow on markets. The rivalry between the world's two largest economies broadened, putting at risk the US listings of Chinese companies and Hong Kong's favoured trade status with the US.

In corporate news, Swiss drugmaker Roche tied up with US peer Gilead Sciences to conduct a late-stage two-drug trial. They hope that mixing Roche's anti-inflammation drug Actemra with Gilead Sciences' anti-viral treatment remdesivir will be more effective than using the latter alone to treat covid-19.

French cosmetics group L'Oreal scrapped plans for a dividend increase and stuck to the 2019 payout level. Its revenue fell in the first quarter as the firm closed stores due to the outbreak, but it remained optimistic about a rebound later this year, led by China.

During the month, we exited the following stocks as they were no longer Shariah-compliant: US video-game firm Activision Blizzard, US healthcare firm Baxter, Japanese drugmaker Chugai Pharmaceutical, German chipmaker Infineon Technologies, French luxury goods firm Kering, Japanese automation firm Nabtesco, US rail provider Norfolk Southern Corp.

To maintain our sectoral exposures at the same level, we initiated Swedish door-security solutions provider Assa Abloy, US drugmaker Pfizer, European software firm SAP and European energy technologies firm Schneider Electric.

Fund Review

The Fund returned 5.61% for the month, outperforming the benchmark return of 5.34% by 0.27%. Year-to-date, the fund returned -1.59%, outperforming the benchmark return of 4.59% by 3.00%.

Ekuiti global meningkat dengan stabil dalam kebanyakan mata wang utama menelusuri Mei. Pelabur optimistik bahawa puncak wabak covid-19 kini telah pun berlalu di kebanyakan negara, serta kebanyakan ekonomi utama berada di landasan pemulihan. Sokongan fiskal yang berterusan terus mendokong saham. Jepun melancarkan 117 trilion yen bajet tambahan yang lebih besar dari jangkaan, manakala Suruhanjaya Eropah mencadangkan dana pemulihan sebanyak €750 bilion euro. Penggubal dasar China melebarkan lagi jurang defisit fiskal yang telah pun besar, mencecah rekod 15.2% dari KDNK. Bagaimanapun, ketegangan AS-China yang timbul semula menyelubungi pasaran. Persaingan antara dua gergasi ekonomi di dunia itu semakin sengit, lalu menempatkan syarikat-syarikat China yang tersenarai di AS dan status keutamaan perdagangan Hong Kong dengan AS dalam jurang bahaya.

Dalam berita korporat, pembuat ubat-ubatan dari Switzerland, Roche bergabung tenaga dengan rakan sejawat AS Gilead Sciences untuk mengendalikan percubaan peringkat akhir melibatkan dua ubat-ubatan. Kedua-duanya berharap bahawa campuran ubat anti-radang Roche Actemra dengan ubat anti-virus Gilead Sciences Remdesivir akan lebih berkesan untuk merawat covid-19 berbanding penggunaan Remdesivir semata-mata.

Kumpulan kosmetik L'Oreal Perancis membatalkan rancangan kenaikan dividen dan tersekat pada tahap pembayaran 2019. Pendapatannya jatuh pada suku pertama apabila firma tersebut menutup operasi ekoran penularan wabak covid-19, namun tetap optimistik tentang pemulihan pada akhir tahun ini, yang dipelopori oleh China.

Semasa bulan yang ditinjau, kami melepaskan pegangan dari saham yang berikut kerana semuanya sudah tidak lagi patuh Shariah: firma permainan video AS Activision Blizzard, firma penjagaan kesihatan AS Baxter, pembuat ubat Jepun Chugai Pharmaceutical, pembuat chip Jerman Infineon Technologies, firma barang mewah Perancis Kering, firma automasi Jepun Nabtesco, dan firma pengendali rel AS Norfolk Southern Corp.

Untuk mengekalkan pendedahan sektor pada tahap yang sama, kami memulakan pegangan dalam pengendali penyelesaian pintu keselamatan Sweden Assa Abloy, pembuat ubat AS Pfizer, firma perisian Eropah SAP dan firma teknologi tenaga Eropah Schneider Electric.

Tinjauan Dana

Dana mencatatkan pulangan 5.61% untuk bulan ini, mengatasi pulangan penanda aras 5.34% sebanyak 0.27%. Sejak awal tahun hingga kini, Dana mengembalikan -1.59%, mengatasi pulangan penanda aras 4.59% sebanyak 4.00%.

Source / Sumber: Fund Commentary, May 2020, N/A

Disclaimer

Investments are subject to investment risks including the possible loss of the principal amount invested. The value of the units may fall as well as rise. Past performances of the funds and that of the fund managers are not necessarily indicative of future performance. The price movements indicated are not reflective of the actual return on your investments (which are subject to your premium allocation rate and deduction charges). The actual return on your invested premiums may fluctuate based on the underlying performance of the investment-linked funds. All Takafulink Dana are invested in Shariah-approved securities and/or Islamic private debt securities. This leaflet is for illustrative purposes only. For further details on the terms and conditions, please refer to the policy document. For further details on how you can invest in these funds, please refer to the respective product brochures. In the event of discrepancy between the information in this fact sheet and the policy document, the information in the policy document shall prevail.

Pelaburan adalah tertakluk kepada risiko-risiko pelaburan termasuk kemungkinan kehilangan jumlah wang pokok yang dilabur. Nilai unit mungkin naik ataupun jatuh. Prestasi masa dulu dana-dana atau pengurus-pengurus dana tidak semestinya mencerminkan prestasi masa depan. Pergerakan harga yang ditunjukkan tidak menggambarkan pulangan sebenar pelaburan anda (yang tertakluk kepada kadar peruntukan premium dan caj potongan). Pulangan sebenar ke atas premium yang anda labur mungkin berbeza, bergantung kepada prestasi dana-dana). Semua Takafulink Dana dilaburkan dalam sekuriti yang diluluskan oleh Syariah dan/atau sekuriti hutang swasta Islam. Risalah ini disediakan hanya untuk gambaran semata-mata. Sila rujuk kepada dokumen polisi untuk keterangan lanjut mengenai terma-terma dan syarat-syarat. Untuk keterangan lanjut mengenai bagaimana anda boleh melabur dalam dana-dana ini, sila rujuk kepada risalah-risalah produk yang berkenaan. Jika terdapat perbezaan di antara helaian fakta dan dokumen polisi, maklumat dalam dokumen polisi dianggap muktamad.

PRUDENTIAL BSN

TAKAFUL